Insider · CIK 0001727172
Douglas M Hunt
Files at PBYI (PUMA BIOTECHNOLOGY, INC.). First filing Jan 3, 2025, latest Jan 8, 2026.
Douglas M Hunt files SEC Form 4 as officer at PBYI (PUMA BIOTECHNOLOGY, INC.). Since Jan 3, 2025, Douglas M Hunt has reported 0 open-market buys worth $0 and 3 open-market sells worth $108k, the latest filed on Jan 8, 2026.
A track record needs three past buys with six months of prices behind them; Douglas M Hunt has 0, so none is measured yet.
The newest scored trade: sold $53k of PBYI on Jan 6, 2026, filed Jan 8, 2026, scored 17 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $53k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PBYI: PUMA BIOTECHNOLOGY, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 17Weak | PUMA BIOTECHNOLOGY, INC. | $53k 8,987 shares | -5% | +114% from low-5% from high | |
| 15Weak | PUMA BIOTECHNOLOGY, INC. | $28k 7,817 shares | -5% | +48% from low-4% from high | |
| 8Weak | PUMA BIOTECHNOLOGY, INC. | $27k 8,633 shares | -6% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 9, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | 3,443 0.01% of outstanding | $12k | Jul 9, 2025 | $15k |
| Jul 8, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | 4,374 0.01% of outstanding | $15k | Jul 8, 2025 | none |
| Jan 2, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | 8,633 0.02% of outstanding | $26k | Jan 2, 2025 | none |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | AGrant or award Common Stock | +49,394 | $0.00 | $0 | 205,301 | Feb 20, 2026 |
| Feb 18, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | AGrant or award Stock Option (Right to Buy)derivative | +70,321 | $0.00 | $0 | 70,321 | Feb 20, 2026 |
| Jan 6, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -3,973 | $5.84 | $23k | 160,921 | Jan 8, 2026 |
| Jan 7, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -5,014 | $5.88 | $29k | 155,907 | Jan 8, 2026 |
| Jul 8, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -4,374 | $3.53 | $15k | 168,337 | Jul 10, 2025 |
| Jul 9, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -3,443 | $3.54 | $12k | 164,894 | Jul 10, 2025 |
| Feb 7, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | AGrant or award Common Stock | +48,117 | $0.00 | $0 | 172,711 | Feb 11, 2025 |
| Feb 7, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | AGrant or award Stock Option (Right to Buy)derivative | +66,604 | $0.00 | $0 | 66,604 | Feb 11, 2025 |
| Jan 2, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -8,633 | $3.15 | $27k | 124,594 | Jan 3, 2025 |
Questions about Douglas M Hunt
Answered from the filings on this page, as of the latest one.
Is Douglas M Hunt buying or selling?
In the last 12 months Douglas M Hunt reported 0 open-market buys worth $0 and 1 open-market sell worth $53k on SEC Form 4; the latest was sold $53k of PBYI on Jan 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Douglas M Hunt's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Douglas M Hunt has 0.
Where does Douglas M Hunt file Form 4?
Douglas M Hunt has filed Form 4 at PBYI (PUMA BIOTECHNOLOGY, INC.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.